Indeed, pre-clinical studies have shown anti-tumor activity of TTCs as monotherapy across a broad range of tumor types, and TTCs targeting HER2, PSMA, MSLN, and CD22 are under investigation in clinical studies. The gene discussed is CD22; the disease is neoplasm.